ArticleCPT: pharmacometrics & systems pharmacology2025
Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi-Mechanistic Pharmacometric Framework.
Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibrutinib, a Bruton's tyrosine kinase (Btk) inhibitor, is a key therapy for chronic lymphocytic leukemia (CLL). In clinical practice, adverse events, such as hypertension, frequently necessitate dose reductions or treatment discontinuation. Emerging evidence suggests that reduced doses may retain clinical efficacy while mitigating toxicity. The synergistic ibrutinib-venetoclax combination remains understudied at low doses, particularly for ibrutinib. This study aimed to explore dose optimization strategies, with/without venetoclax, in treatment-naïve (TN) and relapsed/refractory (R/R) CLL using mechanism-based, model-informed approaches to characterize the relationship between systemic ibrutinib exposure and efficacy and safety biomarkers. We leveraged data from phase 1b/2 and 3 studies, including plasma concentrations, leukocyte and lymphocyte counts, lymph node and spleen size measurements, and blood pressure. A previously developed semi-mechanistic population pharmacokinetic-pharmacodynamic (PKPD) framework was re-evaluated, extended by integrating additional biomarkers and identifying differences between TN and R/R patients, and used to simulate alternative dosing strategies. The model successfully captured the temporal dynamics of all biomarkers simultaneously. We quantified a 76% longer phospho-Btk half-life and a 43% shorter peripheral CLL cell half-life in TN versus R/R patients, with no evidence of ibrutinib resistance in TN patients. Dose reductions based on response depth or toxicity preserved comparable response rates and progression-free survival to standard dosing. Ibrutinib de-escalation schedules with venetoclax resulted in a ≤ 5% reduction in peripheral blood measurable residual disease compared to standard dosing at 2 years. This PKPD framework supports dose individualization to improve tolerability without sacrificing treatment outcomes, offering a path toward more personalized, effective CLL management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.